Title: Syncope
1www.drsarma.in
Superbug
Dr. Sarma. R.V.S.N.
M.D., M.Sc.(Canada), FIMSA, Senior Consultant
Physician Cardio-Metabolic Specialist
2Antimicrobial Resistance
3(No Transcript)
4Lancet Infect Dis 2010 10 597602
Published Online - August 11, 2010
5Worldwide Prevalence of MRSA
Grundmann H et al. Lancet 2006368874.
6Antibiotic Prescriptions
7No Major New Discoveries
8A Changing Landscape for Approved Antibacterials
Resistance
1983-87
1988-92
1993-97
1998-02
2003-05
2008
Bars represent number of new antimicrobial agents
approved by the FDA during that period
- Infectious Diseases Society of America. Bad Bugs,
No Drugs. July 2004 Spellberg B et al. Clin
Infect Dis. 2004381279-1286 - New antimicrobial agents. Antimicrob Agents
Chemother. 2006501912
9Penicillin Cleavage by Penicillinase
Inactive
Active
10Bacterium Resistant to Penicillin
Penicillinase
Plasmid
Gene for b - Lactamase
This organism can freely grow in the presence of
Penicillin
11The Busy Genome Elements of Horizontal Exchange
Genomic islands
e.g. Escherichia Coli Common 4.1 Mb K12 Islands
0.53 Mb 0157H7 Islands 1.34 Mb
Prophages
Conjugative Transposons (gram ve)
Minimal species Genomic backbone
Super Integrons (Mainly ? Protobacteria)
Insertion Sequences
Integrons
Transposons
12Acquisition of Hospital Infections
13Inappropriate Antibiotic Therapy
- Inappropriate empiric antibiotic therapy can lead
to increases in - mortality
- morbidity
- length of hospital stay
- cost burden
- resistance selection
- A number of studies have demonstrated the
benefits of early use of appropriate empiric
antibiotic therapy for patients with nosocomial
infections
14Inappropriate Antibiotic Therapy
- Inappropriate antibiotic therapy can be defined
as one or more of the following - ineffective empiric treatment of bacterial
infection at the time of its identification - the wrong choice, dose or duration of Rx.
- use of an antibiotic to which the pathogen is
resistant
15Mechanism of Antibiotic Resistance
- Antibiotic resistance either arises as a result
of innate consequences or is acquired from other
sources - Bacteria acquire resistance by
- Mutation spontaneous single or multiple changes
in bacterial DNA - Addition of new DNA usually via plasmids, which
can transfer genes from one bacterium to another - Transposons short, specialised sequences of DNA
that can insert into plasmids or bacterial
chromosomes
16Mechanism of Antibiotic Resistance
- Structurally modified antibiotic target site,
resulting in - Reduced antibiotic binding
- Formation of a new metabolic pathway preventing
metabolism of the antibiotic
17Structurally Modified Antibiotic Target Site
Antibiotics normally bind to specific binding
proteins on the bacterial cell surface
Antibiotic
Target site
Binding
Cell wall
Interior of organism
18Structurally Modified Antibiotic Target Site
Antibiotics are no longer able to bind to
modified binding proteins on the bacterial cell
surface
Antibiotic
Modified target site
Cell wall
Interior of organism
Changed site blocked binding
19Altered Uptake Of Antibiotics Decreased
Permeability
- Altered uptake of antibiotics, resulting in
- Decreased permeability
- Increased efflux
20Altered Uptake Of Antibiotics Decreased
Permeability
Antibiotics normally enter bacterial cells via
porin channels in the cell wall
Antibiotic
Porin channel into organism
Cell wall
Interior of organism
21Altered Uptake Of Antibiotics Decreased
Permeability
New porin channels in the bacterial cell wall do
not allow antibiotics to enter the cells
New porin channel into organism
Antibiotic
Cell wall
Interior of organism
22Altered Uptake of Antibiotics Increased Efflux
Antibiotics enter bacterial cells via porin
channels in the cell wall
Porin channel through cell wall
Antibiotic
Entering
Entering
Cell wall
Interior of organism
23Altered Uptake of Antibiotics Increased Efflux
Once antibiotics enter bacterial cells, they are
immediately excluded from the cellsvia active
pumps
Antibiotic
Porin channel through cell wall
Entering
Exiting
Cell wall
Interior of organism
Active pump
24Antibiotics Inactivation (Cleavage)
- Antibiotic inactivation
- Bacteria acquire genes encoding enzymes that
inactivate antibiotics - Examples include
- ?-Lactamases
- Aminoglycoside-modifying enzymes
- Chloramphenicol acetyl transferase
25Antibiotics Inactivation (Cleavage)
Inactivating enzymes target antibiotics
Antibiotic
Enzyme
Target site
Binding
Cell wall
Interior of organism
26Antibiotics Inactivation (Cleavage)
Enzymes bind to antibiotic molecules
Enzymebinding
Antibiotic
Target site
Binding
Enzyme
Cell wall
Interior of organism
27Antibiotics Inactivation (Cleavage)
Enzymes destroy antibiotics or prevent binding to
target sites
Antibiotic altered, binding prevented
Antibioticdestroyed
Antibiotic
Target site
Enzyme
Cell wall
Interior of organism
28Multiple Mechanisms Of Antibacterial Resistance
Modified target
Altered uptake
Drug inactivation
?-lactam
Glycopeptide
Aminoglycoside
Tetracycline
Chloramphenicol
Macrolide
Sulphonamide
Trimethoprim
Quinolones
29?-Lactam Antibiotic Resistance Mechanisms
- Three mechanisms of ?-lactam antibiotic
resistance are recognised - Reduced permeability
- Inactivation with ?-lactamase enzymes
- Altered penicillin-binding proteins (PBPs)
30?-Lactam Antibiotic Resistance Mechanisms
31?-Lactam Antibiotic Resistance
- AmpC and Extended-Spectrum ?-lactamase (ESBL)
production are the most important mechanisms of
?-lactam resistance in nosocomial infections - The antimicrobial and clinical features of these
resistance mechanisms are highlighted in the
following slides
32?-Lactam Resistance AmpC Production
- Worldwide problem
- Incidence increased from 17 to 23 between 1991
and 2001 in UK - Very common in Gram-negative bacilli
- AmpC gene is usually sited on chromosomes, but
can be present on plasmids - Enzyme production is either constitutive
(occurring all the time) or inducible (only
occurring in the presence of the antibiotic)
Pfaller et al. Int J Antimicrob Agents
200219383388 Sader et al. Braz J Infect Dis
1999397110 Livermore et al. Int J Antimicrob
Agents 20032214-27
33?-Lactam Resistance ESBL Production
- An increasing global problem
- Found in a small, expanding group
ofGram-negative bacilli, most commonly the
Entero-bacteriaceae spp. - Usually associated with large plasmids
- Enzymes are commonly mutants of TEM- and
SHV-type ?-lactamases
Jones et al. Int J Antimicrob Agents
200220426431 Sader et al. Diagn Microbiol
Infect Dis 200244273280
34Antimicrobial Features of ESBLs
- Inhibited by ?-lactamase inhibitors
- Usually confer resistance to
- 1, 2 and 3rd generation Cephalosporins eg.
Ceftazidime - Monobactams eg. Aztreonam
- Carboxypenicillins eg. Carbenicillin
- Varied susceptibility to Piperacillin /
Tazobactam - Typically susceptible to Carbapenems and
Cephamycins - Often non-susceptible to fourth generation
Cephalosporins
35Features of methicillin-resistant Staphylococcus
aureus (MRSA)
- Introduction of methicillin in 1959 was
followed rapidly by reports of MRSA isolates - Recognized hospital pathogen since the 1960s
- Major cause of nosocomial infections worldwide
- Contributes to 50 of infectious morbidity in
ICUs - Surveillance studies suggest prevalence has
increased worldwide, reaching 2550 in 1997
Jones. Chest 2001119397S404S
36Emergence of MRSA in the community
- MRSA in hospitals leads to an associated rise
in incidence in the community - Community-acquired MRSA strains may be distinct
from those in hospitals - In a hospital-based study, gt40 of MRSA
infections were acquired prior to admission - Risk factors for community acquisition
included - Recent hospitalization Previous antibiotic
therapy - Residence in a long-term care facility
Intravenous drug use
- Hiramatsu et al. Curr Opin Infect Dis
200215407413 - Layton et al. Infect Control Hosp Epidemiol
1995161217 Naimi et al. 20032902976-2984
37Antimicrobial features of MRSA (1)
- Mechanism involves altered target site
- new penicillin-binding protein PBP 2' (PBP 2a)
- encoded by chromosomally located mecA gene
- Confers resistance to all ?-lactams
- Gene carried on a mobile genetic element
staphylococcal cassette chromosome mec (SCCmec) - Laboratory detection requires care
- Not all mecA-positive clones are resistant to
methicillin
- Hiramatsu et al. Trends Microbiol 20019486493
- Berger-Bachi Rohrer. Arch Microbiol
2002178165171
38Antimicrobial features of MRSA (2)
- Cross-resistance common with many other
antibiotics - Ciprofloxacin resistance is a worldwide problem
in MRSA - involves 2 resistance mutations
- usually involves parC and gyrA genes
- renders organism highly resistant to
ciprofloxacin, with cross-resistance to other
quinolones - Intermediate resistance to glycopeptides first
reported in 1997
- Hiramatsu et al. J Antimicrob Chemother
199740135136 - Hooper. Lancet Infect Dis 20022530538
39Glycopeptide resistance focus on vancomycin
resistance
- Vancomycin-resistant enterococci (VRE)
- Vancomycin-resistant S. aureus (VRSA)
40Features of quinolone resistance Gram-negative
organisms
- Resistance most common in organisms associated
with nosocomial infections - Pseudomonas aeruginosa
- Acinetobacter spp.
- also increasing among ESBL-producing strains
- Meropenem Yearly Susceptibility Test Information
Collection (MYSTIC) surveillance programme
(1997?2000) - 13.4 of Gram-negative strains resistant to
ciprofloxacin - P. aeruginosa and Acinetobacter baumannii are the
most prevalent resistant strains - increasing prevalence of resistance during
surveillance period
- Masterton. J Antimicrob Chemother 200249218220
Thomson. J Antimicrob Chemother 199943(Suppl.
A)3140
41Features of quinolone resistance Gram-positive
organisms
- MRSA
- S. aureus occurred in 22.9 of pneumonias in
hospitalised patients in USA and Canada (1997
SENTRY data) - Enterococcus spp. resistance
- has developed rapidly, especially among VRE
- Streptococcus pneumoniae resistance
- emerging in many countries, including
community-acquired resistance - Hong Kong (12.1), Spain (5.3) and USA (lt1)
- marked cross-resistance with other frequently
used antibiotics
- Hooper. Lancet Infect Dis 20022530538
42Summary
- Antibiotic resistance in the hospital setting is
increasing at an alarming rateand is likely to
have an important impact on infection management - Steps must be taken now to control the increase
in antibiotic resistance
- Cosgrove et al. Arch Intern Med 2002162185190
43Summary
- The Academy for Infection Management supports the
concept of using appropriate antibiotics early in
nosocomial infections and proposes - selecting the most appropriate antibiotic based
on the patient, risk factors, suspected
infection and resistance - administering antibiotics at the right dose for
the appropriate duration - changing antibiotic dosage or therapy based on
resistance and pathogen information - recognising that prior antimicrobial
administration is a risk factor for the presence
of resistant pathogens - knowing the units antimicrobial resistance
profile and choosing antibiotics accordingly
44- Hand washing plays an important role in
nosocomial pneumonias - Wash hands before and after suctioning, touching
ventilator equipment, and/or coming into contact
with respiratory secretions. - Use a continuous subglottic suction ET tube for
intubations expected to be gt 24 hours - Keep the HOB elevated to at least 30 degrees
unless medically contraindicated
45Outline of the talk
- Various Antibiotic Classes
- Mechanisms of action of Anti Bacterials
- Mechanisms of Bacterial Resistance
- Animation on Drug Resistance
- ? Lactamases Drug Resistance
- NDM1 Superbug Concerns
- Other Superbugs Global Issues
- How to prevent Drug Resistance
- Where we are heading in future
46- Various Antibiotic Classes
- Mechanisms of action of Anti Bacterials
- Mechanisms of Bacterial Resistance
- Animation on Drug Resistance
- ? Lactamases Drug Resistance
- NDM1 Superbug Concerns
- Other Superbugs Global Issues
- How to prevent Drug Resistance
- Where we are heading in future
47Bad Bugs, No Drugs1
- The Antimicrobial Availability Task Force of the
IDSA1 identified as particularly problematic
pathogens - A. baumannii and P. aeruginosa
- ESBL-producing Enterobacteriaceae
- MRSA
- Vancomycin-resistant enterococcus
- Declining research investments in antimicrobial
development2
- 1. Infectious Diseases Society of America. Bad
Bugs, No Drugs As Antibiotic Discovery
Stagnates, A Public Health Crisis Brews.
http//www.idsociety.org/pa/IDSA_Paper4_final_web
.pdf. July, 2004. Accessed March 17, 2007. 2.
Talbot GH, et al. Clin Infect Dis. 200642657-68.
48(No Transcript)
49Enterobacteriaceae
- The rapid and disturbing spread of
- extended-spectrum ß-lactamases
- AmpC enzymes
- carbapenem resistance
- metallo-ß-lactamases
- KPC and OXA-48 ß-lactamases
- quinolone resistance
50Extended-Spectrum ß-Lactamases
- ß-lactamases capable of conferring bacterial
resistance to - the penicillins
- first-, second-, and third-generation
cephalosporins - aztreonam
- (but not the cephamycins or carbapenems)
- These enzymes are derived from group 2b
ß-lactamases (TEM-1, TEM-2, and SHV-1) - differ from their progenitors by as few as one AA
51(No Transcript)
52CTX-M-type ESBLs
- Until 2000, most ESBL producers were hospital
Klebsiella spp. with TEM and SHV mutant
ß-lactamases - Now, the dominant ESBLs across most of Europe and
Asia are CTX-M enzymes, which originated as
genetic escapes from Kluyvera spp - Currently recognized as the most widespread and
threatening mechanism of antibiotic resistance,
both in clinical and community settings - 80 of ESBL-positive E. coli from bacteraemias in
the UK and Ireland are resistant to
fluoroquinolones - 40 are resistant to gentamicin
Livermore, DM J. Antimicrob. Chemother 2009
53Carbapenemases
- Ability to hydrolyze penicillins, cephalosporins,
monobactams, and carbapenems - Resilient against inhibition by all commercially
viable ß-lactamase inhibitors - Subgroup 2df OXA (23 and 48) carbapenemases
- Subgroup 2f serine carbapenemases from
molecular class A GES and KPC - Subgroup 3b contains a smaller group of MBLs that
preferentially hydrolyze carbapenems - IMP and VIM enzymes that have appeared globally,
most frequently in non-fermentative bacteria but
also in Enterobacteriaceae
54KPC (K. pneumoniae carbapenemase)
- KPCs are the most prevalent of this group of
enzymes, found mostly on transferable plasmids in
K. pneumoniae - Substrate hydrolysis spectrum includes
cephalosporins and carbapenems
55K. pneumoniae carbapenemase-producing bacteria
- Nordmann P et al. LID 2009
56AmpC ß-lactamases
- Once expressed at high levels, confer resistance
to many ß-lactam antimicrobials (excluding
cefepime and carbapenems) - In E. coli, constitutive over expression of AmpC
ß-lactamases can occur because - of mutations in the promoter and/or attenuator
region (AmpC hyperproducers) - the acquisition of a transferable ampC gene on a
plasmid or other transferable elements
(plasmid-mediated AmpC ß-lactamases)
57Emerging Metallo-ß-Lactamaseswith Mobile
Genetics(SENTRY Program 2001-2005)
58Novel ?-lactams
- Ceftaroline
- Ceftobiprole
- Oral penem
- Faropenem
- Hebeisen P et al. Antimicrob Agents Chemother.
2001. Sader HS et al. Antimicrob Agents
Chemother. 2005. Granizo JJ et al. Clin Ther.
2006. Schurek KN et
al. Expert Rev Anti Infect Ther. 2007.
59Spectrum of Activity
Organism MIC90 (?g/mL) MIC90 (?g/mL) MIC90 (?g/mL) MIC90 (?g/mL)
Organism CTL CBP FAR
Pen-S ?0.016 ?0.015 0.25
Pen-I 0.06 0.12 0.008
Pen-R 0.25 1 1
CTX-R 0.5 1 ND
- Davies TA et al. ICAAC. 2005.
Sahm DF et al. ICAAC. 2006.
Van Bambeke F et al. Drugs.
2007. McGee L et al Morrissey I et
al. ICAAC. 2007.
- Multiple mutations in PBP1a, 2b, and 2x.
MIC90 of 2 mg/L vs. cefuroxime-resistant
strain
60Clinical Utility
ABx Route In vivo Efficacy Cross-Resistance Limitations
CTL IV Good lung penetration in rabbit model None - all active against MDR strains Presumed or reported cross-hypersensitivity to ?-lactams
CBP IV Equal to CTX in murine model None - all active against MDR strains Presumed or reported cross-hypersensitivity to ?-lactams
FAR PO Eradication of S. pneumoniae NI to AMX ? CLV, CPX None - all active against MDR strains Presumed or reported cross-hypersensitivity to ?-lactams
- Boswell FJ et al Jones RN et al. J Antimicrob
Chemother. 2002. Azoulay-Dupuis E
et al. Antimicrob Agents Chemother. 2004.
Echols R et al Kowalsky S et
al Lentnek A et al Drehobl M et al. ICAAC.
2005. Jacqueline C et al
Young C et al Rubino CM et al. ICAAC. 2006.
61Novel Glycopeptides
- Dalbavancin
- Once weekly IV dosing
- Oritavancin
- Telavancin
- Versus vancomycin
- Additional mechanisms of action
- Renal and hepatic excretion
- No known nephrotoxicity or dose adjustments
- Malabarba A et al. J Antimicrob Chemother. 2005
62Spectrum of Activity
Organism MIC90 (?g/mL) MIC90 (?g/mL) MIC90 (?g/mL) MIC90 (?g/mL)
Organism VAN DAL ORI TEL
Pen-S 0.5 0.03 0.004 0.03
Pen-NS 0.25-2 0.03 0.008 0.015
MDR ND ND 0.008 0.03
- Rapidly bactericidal
Also active
against macrolide- and FQ-resistant strains
- Streit JM et al. Diag Micro Infect Dis. 2004.
Lin G et al.
ICAAC. 2005.
Thornsberry C et al. ICAAC. 2006.
Draghi
DC et al Grover PK et al Fritsche TR et al.
ICAAC. 2007.
63Clinical Utility
ABx Route In vivo Efficacy Cross-Resistance AEs
DAL IV Animal model of PCN-resistant NBPP Partial with vancomycin clinical significance unclear Redman syndrome with TEL Rare ? in platelets
ORI IV High AUCMIC ratios in ELF and plasma in murine NBPP Partial with vancomycin clinical significance unclear Redman syndrome with TEL Rare ? in platelets
TEL IV Good penetration into ELF and AMs in human volunteers Phase III trial pending Partial with vancomycin clinical significance unclear Redman syndrome with TEL Rare ? in platelets
- Gotfried M et al. ICAAC. 2005. Lehoux
D et al. ICAAC. 2007.
64Novel Fluoroquinolone
- Garenoxacin (PO/IV)
- Bactericidal
- MIC90 0.06 ?g/mL for penicillin-, macrolide-,
and ? 6 drug- resistant S. pneumoniae - MIC90 1 ?g/mL for CIP- and LEV- resistant S.
pneumoniae - More potent than MOX
- Wu P et al. Antimicrob Agents Chemother. 2001.
Jones RN et al. Diag Micro Infect Dis. 2007.
65Polymyxins
- a group of polypeptide antibiotics that consists
of 5 chemically different compounds (polymyxins
A-E), were discovered in 1947 - Only polymyxin B and polymyxin E (colistin) have
been used in clinical practice - the primary route of excretion is renal
66Colistin
- The target of antimicrobial activity of colistin
is the bacterial cell membrane - Colistin has also potent anti-endotoxin activity
- The endotoxin of G-N bacteria is the lipid A
portion of LPS molecules, and colistin binds and
neutralizes LPS
67Colistin
- Active
- Acinetobacter species,
- Pseudomonas aeruginosa,
- Enterobacteriaciae
68Colistin
- 160 mg (2 million IU) ever 8 h
- 240 mg (3 million IU) every 8 h for
life-threatening infections
69Colistin
- Dose adjustment for renal failure
- Adverse effects
- nephrotoxicity (acute tubular necrosis)
- neurotoxicity (dizziness, weakness, facial
paresthesia, vertigo, visual disturbances,
confusion, ataxia, and neuromuscular blockade,
which can lead to respiratory failure or apnea)
70Ceftobiprole (Zeftera)
- June 30, 2008 -- Health Canada has authorised the
marketing of ceftobiprole medocaril for injection
(Zeftera and marketed by Janssen Ortho) for the
treatment of complicated skin and soft tissue
infections including diabetic foot infections
71Daptomycin (Cubicin)
- On September 24, 2007, Health Canada approved
daptomycin intravenous infusion (Cubicin, Cubist
Pharmaceuticals, Inc, and marketed by Oryx
Pharmaceuticals, Inc) for the treatment of
complicated skin and skin structure infections
caused by certain gram-positive infections and
for bloodstream infections, including right-sided
infective endocarditis, caused by S. aureus.
72Daptomycins Mechanism of Action
- Irreversibly binds to cell membrane of
Gram-positive bacteria - Calcium-dependent membrane insertion of molecule
- Rapidly depolarizes the cell membrane
- Efflux of potassium
- Destroys ion-concentrationgradient
73- Mechanism of action of Anti bacterials
- Mechanism of Bacterial Resistance
- Second level
- Third level
- Fourth level
- Fifth level